🇬🇧🇮🇹 Vincenzo is a Christian, a husband, a dad, a theologian, an apologist, a scientist, a polyglot, and an anglicised Neapolitan. Not always in this order.
JCI Insight – A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2
— Read on insight.jci.org/articles/view/146316
The “new virus”. I predicted pre existing immunity to it ages ago. Both B and T cells immunity, even cross reactive, is now a fact. The mass vaccination programme makes no sense, unless other reasons for it are taken into account.
Ivermectin for Prevention and Treatment of COVID-19 Infectio… : American Journal of Therapeutics
— Read on journals.lww.com/americantherapeutics/Abstract/9000/Ivermectin_for_Prevention_and_Treatment_of.98040.aspx
Ivermectin works. It’s been working since April 2020. Thanks for letting people die needlessly.
People who recover from mild COVID-19 have bone-marrow cells that can churn out antibodies for decades, although viral variants could dampen some of the protection they offer.
— Read on www.nature.com/articles/d41586-021-01442-9
New Study Links Ivermectin to ‘Large Reductions’ in COVID-19 Deaths
— Read on m.theepochtimes.com/new-study-links-ivermectin-to-large-reductions-in-covid-19-deaths_3867278.html/amp
Considering the urgency of the ongoing COVID-19 pandemic, detection of various new mutant strains and future potential re-emergence of novel coronaviruses, repurposing of approved drugs such as Ivermectin could be worthy of attention. This evidence-based review article aims to discuss the mechanism of action of ivermectin against SARS-CoV-2 and summarizing the available literature over the years. A schematic of the key cellular and biomolecular interactions between Ivermectin, host cell, and SARS-CoV-2 in COVID-19 pathogenesis and prevention of complications have been proposed.
— Read on www.nature.com/articles/s41429-021-00430-5
Cross-reactive antibody immunity against SARS-CoV-2 in children and adults | Cellular & Molecular Immunology
— Read on www.nature.com/articles/s41423-021-00700-0
More evidence that nobody needed Covid vaccines in the first place.
Not-yet-peer-reviewed observational study confirms the efficacy of HCQ+AZ against Covid-19:
 Since higher dose HCQ/AZM therapy improves survival by nearly 200% in this population, the safety data are moot.
SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
— Read on www.ncbi.nlm.nih.gov/research/coronavirus/
Vaccine efficacy is generally reported as a relative risk reduction (RRR). It uses the relative risk (RR)—ie, the ratio of attack rates with and without a vaccine—which is expressed as 1–RR. Ranking by reported efficacy gives relative risk reductions of 95% for the Pfizer–BioNTech, 94% for the Moderna–NIH, 90% for the Gamaleya, 67% for the J&J, and 67% for the AstraZeneca–Oxford vaccines. However, RRR should be seen against the background risk of being infected and becoming ill with COVID-19, which varies between populations and over time. Although the RRR considers only participants who could benefit from the vaccine, the absolute risk reduction (ARR), which is the difference between attack rates with and without a vaccine, considers the whole population. ARRs tend to be ignored because they give a much less impressive effect size than RRRs: 1.3% for the AstraZeneca–Oxford, 1.2% for the Moderna–NIH, 1.2% for the J&J, 0.93% for the Gamaleya, and 0.84% for the Pfizer–BioNTech vaccines.
COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room
Mask mandates and use are not associated with slower state-level COVID-19 spread during COVID-19 growth surges
— Read on www.medrxiv.org/content/10.1101/2021.05.18.21257385v1